Cellectis reports promising data for lasme-cel in r/r B-ALL
PositiveFinancial Markets

Cellectis has announced promising results for its innovative therapy, lasme-cel, in treating relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This development is significant as it offers hope for patients who have limited treatment options, showcasing advancements in cancer therapies that could improve survival rates and quality of life.
— Curated by the World Pulse Now AI Editorial System